A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.
Phase:
PHASE2
Details
Lead Sponsor:
Nantong Bencao Quadriga Medical Technology Co. Ltd.